Cargando…
We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity
Observational studies, from multiple countries, repeatedly demonstrate an association between obesity and severe COVID-19, which is defined as need for hospitalization, intensive care unit admission, invasive mechanical ventilation (IMV) or death. Meta-analysis of studies from China, USA, and France...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930643/ https://www.ncbi.nlm.nih.gov/pubmed/33648370 http://dx.doi.org/10.1177/2150132721996283 |
_version_ | 1783660138830233600 |
---|---|
author | Dutta, Nirjhar Ingraham, Nicholas E. Usher, Michael G. Fox, Claudia Tignanelli, Christopher J. Bramante, Carolyn T. |
author_facet | Dutta, Nirjhar Ingraham, Nicholas E. Usher, Michael G. Fox, Claudia Tignanelli, Christopher J. Bramante, Carolyn T. |
author_sort | Dutta, Nirjhar |
collection | PubMed |
description | Observational studies, from multiple countries, repeatedly demonstrate an association between obesity and severe COVID-19, which is defined as need for hospitalization, intensive care unit admission, invasive mechanical ventilation (IMV) or death. Meta-analysis of studies from China, USA, and France show odds ratio (OR) of 2.31 (95% CI 1.3-4.1) for obesity and severe COVID-19. Other studies show OR of 12.1 (95% CI 3.25-45.1) for mortality and OR of 7.36 (95% CI 1.63-33.14) for need for IMV for patients with body mass index (BMI) ≥ 35 kg/m(2). Obesity is the only modifiable risk factor that is not routinely treated but treatment can lead to improvement in visceral adiposity, insulin sensitivity, and mortality risk. Increasing the awareness of the association between obesity and COVID-19 risk in the general population and medical community may serve as the impetus to make obesity identification and management a higher priority. |
format | Online Article Text |
id | pubmed-7930643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-79306432021-03-12 We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity Dutta, Nirjhar Ingraham, Nicholas E. Usher, Michael G. Fox, Claudia Tignanelli, Christopher J. Bramante, Carolyn T. J Prim Care Community Health Commentaries Observational studies, from multiple countries, repeatedly demonstrate an association between obesity and severe COVID-19, which is defined as need for hospitalization, intensive care unit admission, invasive mechanical ventilation (IMV) or death. Meta-analysis of studies from China, USA, and France show odds ratio (OR) of 2.31 (95% CI 1.3-4.1) for obesity and severe COVID-19. Other studies show OR of 12.1 (95% CI 3.25-45.1) for mortality and OR of 7.36 (95% CI 1.63-33.14) for need for IMV for patients with body mass index (BMI) ≥ 35 kg/m(2). Obesity is the only modifiable risk factor that is not routinely treated but treatment can lead to improvement in visceral adiposity, insulin sensitivity, and mortality risk. Increasing the awareness of the association between obesity and COVID-19 risk in the general population and medical community may serve as the impetus to make obesity identification and management a higher priority. SAGE Publications 2021-03-01 /pmc/articles/PMC7930643/ /pubmed/33648370 http://dx.doi.org/10.1177/2150132721996283 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Commentaries Dutta, Nirjhar Ingraham, Nicholas E. Usher, Michael G. Fox, Claudia Tignanelli, Christopher J. Bramante, Carolyn T. We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity |
title | We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity |
title_full | We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity |
title_fullStr | We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity |
title_full_unstemmed | We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity |
title_short | We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity |
title_sort | we should do more to offer evidence-based treatment for an important modifiable risk factor for covid-19: obesity |
topic | Commentaries |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930643/ https://www.ncbi.nlm.nih.gov/pubmed/33648370 http://dx.doi.org/10.1177/2150132721996283 |
work_keys_str_mv | AT duttanirjhar weshoulddomoretoofferevidencebasedtreatmentforanimportantmodifiableriskfactorforcovid19obesity AT ingrahamnicholase weshoulddomoretoofferevidencebasedtreatmentforanimportantmodifiableriskfactorforcovid19obesity AT ushermichaelg weshoulddomoretoofferevidencebasedtreatmentforanimportantmodifiableriskfactorforcovid19obesity AT foxclaudia weshoulddomoretoofferevidencebasedtreatmentforanimportantmodifiableriskfactorforcovid19obesity AT tignanellichristopherj weshoulddomoretoofferevidencebasedtreatmentforanimportantmodifiableriskfactorforcovid19obesity AT bramantecarolynt weshoulddomoretoofferevidencebasedtreatmentforanimportantmodifiableriskfactorforcovid19obesity |